Browsing Tag
Eris Lifesciences
5 posts
NATCO Pharma (NSE: NATCOPHARM) launches cheapest semaglutide in India at Rs 1,290 on Day 1 of patent expiry
NATCO Pharma launches generic semaglutide in India at INR 1,290 on Day 1 of patent expiry. What it means for GLP-1 markets. Read the full analysis.
Can Jagsonpal Pharmaceuticals’ dermatology push turn into a breakout growth segment?
Jagsonpal Pharmaceuticals is expanding its dermatology portfolio, aiming to turn anti-fungal and skin-care therapies into its next big growth driver in India.
Eris Lifesciences acquires Biocon Biologics’ branded formulation business for Rs 1,242cr
In a strategic move that reshapes the landscape of India’s injectables market, Eris Lifesciences Ltd., a leading player…
Eris Lifesciences strikes deal for Dr. Reddy’s cosmetic dermatology brands
Eris Lifesciences has announced the acquisition of nine cosmetic dermatology brands in the Indian market from Dr. Reddy’s…
Eris Lifesciences acquires nine Glenmark Pharmaceuticals dermatology brands in INR340.48 crore deal
Eris Lifesciences’ ₹340.48 crore purchase of nine Glenmark Pharmaceuticals dermatology brands reshapes India’s pharma market. See how it impacts strategy and growth.